<?xml version='1.0' encoding='utf-8'?>
<document id="28786954"><sentence text="Time- and NADPH-Dependent Inhibition on CYP3A by Gomisin A and the Pharmacokinetic Interactions between Gomisin A and Cyclophosphamide in Rats."><entity charOffset="49-58" id="DDI-PubMed.28786954.s1.e0" text="Gomisin A" /><entity charOffset="104-113" id="DDI-PubMed.28786954.s1.e1" text="Gomisin A" /><entity charOffset="118-134" id="DDI-PubMed.28786954.s1.e2" text="Cyclophosphamide" /><pair ddi="false" e1="DDI-PubMed.28786954.s1.e0" e2="DDI-PubMed.28786954.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28786954.s1.e0" e2="DDI-PubMed.28786954.s1.e1" /><pair ddi="false" e1="DDI-PubMed.28786954.s1.e0" e2="DDI-PubMed.28786954.s1.e2" /><pair ddi="false" e1="DDI-PubMed.28786954.s1.e1" e2="DDI-PubMed.28786954.s1.e1" /><pair ddi="false" e1="DDI-PubMed.28786954.s1.e1" e2="DDI-PubMed.28786954.s1.e2" /></sentence><sentence text="The traditional Chinese medicine Schisandra chinensis has remarkable protective effects against chemical-induced toxicity" /><sentence text=" Cyclophosphamide (CTX), in spite advances in chemotherapy and immunosuppressive regimes, is prone to cause severe toxicity due to its chloroacetaldehyde (CAA) metabolite produced by CYP3A"><entity charOffset="1-17" id="DDI-PubMed.28786954.s3.e0" text="Cyclophosphamide" /><entity charOffset="19-22" id="DDI-PubMed.28786954.s3.e1" text="CTX" /><entity charOffset="135-153" id="DDI-PubMed.28786954.s3.e2" text="chloroacetaldehyde" /><entity charOffset="155-158" id="DDI-PubMed.28786954.s3.e3" text="CAA" /><pair ddi="false" e1="DDI-PubMed.28786954.s3.e0" e2="DDI-PubMed.28786954.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28786954.s3.e0" e2="DDI-PubMed.28786954.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28786954.s3.e0" e2="DDI-PubMed.28786954.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28786954.s3.e0" e2="DDI-PubMed.28786954.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28786954.s3.e1" e2="DDI-PubMed.28786954.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28786954.s3.e1" e2="DDI-PubMed.28786954.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28786954.s3.e1" e2="DDI-PubMed.28786954.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28786954.s3.e2" e2="DDI-PubMed.28786954.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28786954.s3.e2" e2="DDI-PubMed.28786954.s3.e3" /></sentence><sentence text=" Our previous study identified that S" /><sentence text=" chinensis extract (SCE) co-administration potently decreased CAA production and attenuated liver, kidney and brain injuries in CTX-treated rats"><entity charOffset="128-130" id="DDI-PubMed.28786954.s5.e0" text="CTX" /><entity charOffset="62-64" id="DDI-PubMed.28786954.s5.e1" text="CAA" /><pair ddi="false" e1="DDI-PubMed.28786954.s5.e1" e2="DDI-PubMed.28786954.s5.e1" /><pair ddi="false" e1="DDI-PubMed.28786954.s5.e1" e2="DDI-PubMed.28786954.s5.e0" /></sentence><sentence text=" Gomisin A (Gom A) is proved to be one of the most abundant bioactive lignans in S"><entity charOffset="1-10" id="DDI-PubMed.28786954.s6.e0" text="Gomisin A" /></sentence><sentence text=" chinensis with a significant CYP3A inhibitory effect" /><sentence text=" To find out whether and how Gom A participated in the chemoprevention of SCE against CTX toxicity, the Gom A-caused CYP3A inhibition in vitro as well as the pharmacokinetic interactions between Gom A and CTX in vivo were examined in this study"><entity charOffset="86-94" id="DDI-PubMed.28786954.s8.e0" text="CTX" /><entity charOffset="205-213" id="DDI-PubMed.28786954.s8.e1" text="CTX" /><pair ddi="false" e1="DDI-PubMed.28786954.s8.e0" e2="DDI-PubMed.28786954.s8.e0" /><pair ddi="false" e1="DDI-PubMed.28786954.s8.e0" e2="DDI-PubMed.28786954.s8.e1" /></sentence><sentence text=" Using human liver microsomes, a reversible inhibition assay revealed that Gom A was a competitive inhibitor with a KI value of 1" /><sentence text="10 µM, and the time- and NADPH-dependent CYP3A inhibition of Gom A was observed in a time-dependent inhibition assay (KI = 0" /><sentence text="35 µM, kinact = 1" /><sentence text="96 min-1)" /><sentence text=" Hepatic CYP3A mRNA expression experienced a significant increase in our rat model with Gom A administration" /><sentence text=" This explained why CAA production decreased in the 0"><entity charOffset="20-22" id="DDI-PubMed.28786954.s14.e0" text="CAA" /></sentence><sentence text="5 h- and 6 h-pretreatment rat groups while it increased in the 24 h- and 72 h-pretreatment groups, indicating a bidirectional effect of Gom A on CYP3A-mediated CTX metabolism"><entity charOffset="160-162" id="DDI-PubMed.28786954.s15.e0" text="CTX" /></sentence><sentence text=" The present study suggested that Gom A participates like SCE in the pharmacokinetic intervention of CTX by blocking CYP3A-mediated metabolism and reducing CAA production, and thus plays an important role in the chemopreventive activity of S"><entity charOffset="101-103" id="DDI-PubMed.28786954.s16.e0" text="CTX" /><entity charOffset="156-158" id="DDI-PubMed.28786954.s16.e1" text="CAA" /><pair ddi="false" e1="DDI-PubMed.28786954.s16.e0" e2="DDI-PubMed.28786954.s16.e0" /><pair ddi="false" e1="DDI-PubMed.28786954.s16.e0" e2="DDI-PubMed.28786954.s16.e1" /></sentence><sentence text=" chinensis against CTX toxicity, in addition to the previously recognized protective effects"><entity charOffset="19-21" id="DDI-PubMed.28786954.s17.e0" text="CTX" /></sentence><sentence text=" Also, the combined use of S" /><sentence text=" chinensis preparation or other drugs containing Gom A as the main component with CTX needed to be addressed for better clinical intervention"><entity charOffset="82-84" id="DDI-PubMed.28786954.s19.e0" text="CTX" /></sentence><sentence text="" /></document>